| Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead H Ekhtiari, H Tavakoli, G Addolorato, C Baeken, A Bonci, S Campanella, ... Neuroscience & Biobehavioral Reviews 104, 118-140, 2019 | 293 | 2019 |
| The neurobiology of impulsivity and substance use disorders: implications for treatment K Kozak, AM Lucatch, DJE Lowe, IM Balodis, J MacKillop, TP George Annals of the New York Academy of Sciences 1451 (1), 71-91, 2019 | 253 | 2019 |
| A review of brain stimulation methods to treat substance use disorders AS Coles, K Kozak, TP George The American journal on addictions 27 (2), 71-91, 2018 | 169 | 2018 |
| Neurobiological determinants of tobacco smoking in schizophrenia AM Lucatch, DJE Lowe, RC Clark, K Kozak, TP George Frontiers in psychiatry 9, 672, 2018 | 62 | 2018 |
| Effects of short-term, high-frequency repetitive transcranial magnetic stimulation to bilateral dorsolateral prefrontal cortex on smoking behavior and cognition in patients … K Kozak, M Sharif-Razi, M Morozova, EV Gaudette, MS Barr, ... Schizophrenia research 197, 441-443, 2018 | 44 | 2018 |
| Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls RA Rabin, K Kozak, KK Zakzanis, G Remington, TP George Schizophrenia research 194, 55-61, 2018 | 28 | 2018 |
| A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls RA Rabin, K Kozak, KK Zakzanis, G Remington, C Stefan, AJ Budney, ... Schizophrenia research 194, 47-54, 2018 | 22 | 2018 |
| A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness K Kozak, P H. Smith, DJE Lowe, AH Weinberger, ZD Cooper, RA Rabin, ... The American journal of drug and alcohol abuse 47 (5), 535-547, 2021 | 20 | 2021 |
| Pharmacotherapy for smoking cessation in schizophrenia: a systematic review K Kozak, TP George Expert opinion on pharmacotherapy 21 (5), 581-590, 2020 | 20 | 2020 |
| Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia KK Bidzinski, DJE Lowe, M Sanches, M Sorkhou, I Boileau, M Kiang, ... Schizophrenia 8 (1), 2, 2022 | 16 | 2022 |
| Traits and biomarkers for addiction risk in schizophrenia K Kozak, MS Barr, TP George Current Addiction Reports 4, 14-24, 2017 | 16 | 2017 |
| Extracellular stress stimuli alter galectin expression profiles and adhesion characteristics of HL-60 cells AV Timoshenko, J Lanteigne, K Kozak Molecular and cellular biochemistry 413, 137-143, 2016 | 13 | 2016 |
| Effects of varenicline on cognitive function in non-smokers with schizophrenia. K Kozak, SS Dermody, RA Rabin, M Zack, MS Barr, RF Tyndale, ... Elsevier Science, 2018 | 9 | 2018 |
| Effects of Tobacco Smoking Status on Verbal Learning and Memory in Patients With Schizophrenia and Non‐Psychiatric Controls K Kozak, DJE Lowe, TP George The American Journal on Addictions 28 (6), 503-511, 2019 | 5 | 2019 |
| E-cigarettes D Lowe, AS Coles, TP George, K Kozak The Assessment and Treatment of Addiction, 43-56, 2019 | 5 | 2019 |
| Neuropsychological and neurophysiological measures associated with changes in cannabis use and rTMS treatment response in schizophrenia D Lowe, K Kozak, T George Biological Psychiatry 87 (9), S425, 2020 | 1 | 2020 |
| Effects of the nicotinic partial agonist varenicline on smoking lapse behaviour in schizophrenia K Kozak, SS Dermody, M Sharif-Razi, AS Coles, M Morozova, VC Wing, ... Canadian Journal of Addiction 10 (2), 27-35, 2019 | 1 | 2019 |
| Dose effects of varenicline on cognition as a function of smoking status in schizophrenia and non-psychiatric controls K Kozak, T George Neuropsychopharmacology 43, S607-S608, 2017 | 1 | 2017 |
| 678. Differential Effects of Cannabis versus Tobacco on Theta-Gamma Coupling in Schizophrenia M Barr, R Zomorrodi, M Goodman, K Kozak, J Ramlakan, A Coles, ... Biological Psychiatry 81 (10), S274-S275, 2017 | 1 | 2017 |
| 175. Effects of the nicotinic partial agonist varenicline on smoking lapse in smokers with and without schizophrenia A Coles, K Kozak, M Sharif-Razi, S McKee, T George Biological Psychiatry 81 (10), S73, 2017 | 1 | 2017 |
Tony P GeorgeProfessor of Psychiatry, University of Toronto; Chief, Schizophrenia Division, CAMHBestätigte E-Mail-Adresse bei utoronto.ca